What does xtandi treat

What is Xtandi (Enzalutamide)?

Xtandi, with the generic name enzalutamide, is a powerful oral medication belonging to a class of drugs known as androgen receptor inhibitors. It is specifically designed to combat prostate cancer by interfering with the hormonal signals that promote the growth of cancer cells. Prostate cancer cells, especially in advanced stages, often rely on male hormones called androgens, such as testosterone, to grow and multiply. Xtandi works by blocking these androgens from reaching the cancer cells and signaling them to grow.

Conditions Treated by Xtandi

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The most common and primary indication for Xtandi is the treatment of metastatic castration-resistant prostate cancer (mCRPC). 'Metastatic' means that the cancer has spread from the prostate gland to other parts of the body, such as the bones or lymph nodes. 'Castration-resistant' refers to a stage where the cancer continues to grow even when the body's testosterone levels have been reduced to very low levels, typically through medical or surgical castration (androgen deprivation therapy or ADT).

In patients with mCRPC, Xtandi has demonstrated significant efficacy in delaying disease progression and improving overall survival. Clinical trials have shown that Xtandi can help slow down the growth of tumors, reduce the risk of skeletal-related events (like fractures), and extend the lifespan of men diagnosed with this advanced form of prostate cancer. It is often prescribed when other treatments, including ADT and chemotherapy, are no longer effective.

Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

Xtandi is also approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC). In this condition, the cancer has not spread to distant parts of the body, but it has become resistant to hormone therapy. A key indicator for this use is a rapidly rising prostate-specific antigen (PSA) level, which suggests that the cancer is still growing despite low testosterone levels.

The approval for nmCRPC is based on studies showing that Xtandi can significantly delay the development of metastases (spread of cancer) and improve overall survival compared to placebo. By initiating treatment with Xtandi at this earlier stage of castration resistance, physicians aim to prevent or delay the spread of cancer, thereby preserving the patient's quality of life for a longer period.

How Xtandi Works

Xtandi functions by targeting the androgen receptor (AR) signaling pathway. Androgens bind to ARs within prostate cancer cells, triggering a cascade of events that promotes cell growth and survival. Xtandi inhibits this process in multiple ways:

• Inhibits Androgen Binding: It strongly competes with androgens for binding to the AR.
• Prevents AR Nuclear Translocation: It stops the AR from moving into the cell nucleus, where it typically interacts with DNA to promote gene expression.
• Reduces AR Expression: It may also reduce the overall amount of AR protein in the cancer cells.

By disrupting these critical steps, Xtandi effectively deprives the prostate cancer cells of the signals they need to grow, leading to tumor shrinkage or slowed progression.

Administration and Dosage

Xtandi is an oral medication, meaning it is taken by mouth. It is typically prescribed as soft gel capsules. Patients are usually instructed to take a specific dose once daily. It is important for patients to follow their doctor's instructions carefully regarding dosage and timing, and to not miss doses or alter the regimen without medical consultation. The medication is generally well-tolerated, but like all drugs, it can have side effects.

Potential Side Effects

While Xtandi can be very effective, it is associated with potential side effects. Common side effects may include fatigue, back pain, diarrhea, joint pain, hot flashes, and headache. More serious side effects can occur, such as seizures, posterior reversible encephalopathy syndrome (PRES), and cardiovascular events. It is crucial for patients to discuss any side effects they experience with their healthcare provider promptly.

Xtandi in the Treatment Landscape

Xtandi represents a significant advancement in the treatment of advanced prostate cancer. It offers an effective oral option for patients who have become resistant to standard hormone therapies. Its ability to delay disease progression and improve survival makes it a cornerstone therapy for both metastatic and non-metastatic castration-resistant prostate cancer. The decision to use Xtandi, like any cancer treatment, is made by a qualified oncologist based on the individual patient's cancer stage, overall health, and previous treatments.